NCT00674102已完成1 期
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- To assess the safety profile and tolerability of ASA404 when administered in combination with paclitaxel and carboplatin in Japanese patients with non small cell lung cancer
研究概览
简要总结
The safety, tolerability, efficacy and pharmacokinetics of ASA404 when administered in combination with paclitaxel and Carboplatin are assessed. ASA404 is administered intravenously every 21 days to Japanese patients with Non small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
ASA404
Experimental
干预措施: ASA404 (Drug)
结局指标
主要结局
To assess the safety profile and tolerability of ASA404 when administered in combination with paclitaxel and carboplatin in Japanese patients with non small cell lung cancer
时间窗: First cycle
次要结局
- To characterize the pharmacokinetics profile of ASA404 in Japanese patients(every 2 cycles)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal FunctionMetastatic CancerNCT01278758Novartis Pharmaceuticals7
已完成
1 期
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid TumorsAdvanced or Recurrent Solid TumorsNCT01285453Novartis Pharmaceuticals9
撤回
1 期
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid TumorsTumorsNCT01031212University of California, San Francisco
已完成
1 期
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.Advanced Solid TumorAdult DiseaseLung CancerNCT04855929Anaveon AG55
终止
1 期
Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 InhibitorSolid TumorsNCT01299415Novartis Pharmaceuticals17